Posted by Michael Wonder on 26 Oct 2023
Valneva submits Chikungunya vaccine marketing application to EMA and announces CHMP accelerated assessment
25 October 2023 - Valneva today announces the submission of a marketing application with the EMA for approval of the Company’s single shot chikungunya vaccine candidate, VLA1553.
Valneva was also granted accelerated assessment for the application by EMA’s CHMP based on the vaccine candidate’s “major interest for public health and therapeutic innovation”.
